929 results match your criteria Pediatric Drugs[Journal]


Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study.

Paediatr Drugs 2018 Dec 17. Epub 2018 Dec 17.

Division of Gastroenterology, Departments of Medicine and Pediatrics, Research Institute of the McGIll University Health Centre, 1650 Cedar Avenue C10.145, Montreal, QC, H3G 1A4, Canada.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects both patients and their families. Current therapies often alleviate symptoms but do not prevent or eradicate the disease.

Objectives: Our objective was to determine whether pancreatic enzyme supplementation is an effective and safe treatment in refractory pediatric AD associated with food allergies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0321-1DOI Listing
December 2018
1 Read

Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals.

Paediatr Drugs 2018 Dec 13. Epub 2018 Dec 13.

Division of Rheumatology, Children's Mercy Kansas City, 2401 Gillham Road, Kansas City, MO, 64108, USA.

Background: Arthropathy of Down syndrome (DA) is largely under-recognized, with an average 2-year delay in diagnosis. Most patients present with polyarthritis, and treatment has historically been challenging.

Objectives: Our objective was to investigate the clinical features and treatment of DA in the largest cohort reported to date. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0322-0
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0322-0DOI Listing
December 2018
1 Read

Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review.

Paediatr Drugs 2018 Nov 28. Epub 2018 Nov 28.

Office of Pediatric Therapeutics, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Avenue, Building 32, Room 5158, Silver Spring, MD, 20993, USA.

Objectives: Half of prescription drugs commonly given to children lack product labeling on pediatric safety, efficacy, and dosing. Two drugs most widely used off-label in pediatrics are azithromycin and fentanyl. We sought to determine the risk of serious adverse events (SAEs) when oral azithromycin or intravenous/intramuscular fentanyl are used off-label compared to on-label in pediatric intensive care units (ICUs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0318-9DOI Listing
November 2018

Topical Pharyngeal Lidocaine Reduces Respiratory Adverse Events During Upper Gastrointestinal Endoscopies Under Ketamine Sedation in Children.

Paediatr Drugs 2018 Nov 27. Epub 2018 Nov 27.

Mother and Child Health, and Radiology Department, Cádiz University, Cadiz, Spain.

Background: Upper gastrointestinal endoscopies (UGEs) performed under ketamine sedation may increase the risk of respiratory adverse events (RAEs) due to pharyngeal stimulation. Topical lidocaine prevents general anesthesia-induced laryngospasm.

Objective: Our objective was to determine whether topical lidocaine may reduce the incidence of RAEs induced by pharyngeal stimulation in UGEs performed on children sedated with ketamine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0320-2DOI Listing
November 2018
2 Reads

Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.

Paediatr Drugs 2018 Dec;20(6):593-600

, Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disease that is typically characterized by the abnormal BCR-ABL1 fusion gene on the Philadelphia (Ph) chromosome in neoplastic cells. Dasatinib (Sprycel) is an orally administered, small molecule tyrosine kinase inhibitor indicated for the treatment of certain hematological malignancies, including Ph-positive CML in the chronic phase (Ph+ CML-CP) in adult and pediatric patients. In open-label phase 1 and phase 2 clinical trials, dasatinib produced early and durable target responses (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0319-8DOI Listing
December 2018
3 Reads

Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.

Paediatr Drugs 2018 Dec;20(6):585-591

Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.

Background: We sought to quantify the degree of anemia after high-dose intravenous immunoglobulin (IVIG) therapy in patients with Kawasaki disease (KD) by assessing hemoglobin (Hb) dynamics and determining the risk of transfusion.

Methods: We analyzed data from a database containing inpatient data collected from 230 hospitals in Japan. In addition to administrative records, this database included laboratory results for some patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0316-yDOI Listing
December 2018
2 Reads

Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review.

Paediatr Drugs 2018 Dec;20(6):555-566

The Department of Cystic Fibrosis and Chronic Lung Infection, National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, 1B Manresa Road, London, SW36LR, UK.

Cystic fibrosis is the most common inherited condition in the Caucasian population and is associated with significantly reduced life expectancy. Recent advances in treatment have focussed on addressing the underlying cause of the condition, the defective production, expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Several drugs with different modes of action have produced promising results in clinical trials, and some have been incorporated into routine clinical care for specific patients in many countries worldwide. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0315-z
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0315-zDOI Listing
December 2018
4 Reads

Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.

Paediatr Drugs 2018 Dec;20(6):523-537

Division of Gastroenterology, Hepatology and Nutrition, Center for Functional Motility Disorders, Nationwide Children's Hospital, Columbus, OH, 43205, USA.

Gastroesophageal reflux (GER) is the retrograde movement of gastric (and sometimes duodenal) contents into the esophagus. While the majority of GER is physiologic, for patients, it can be associated with symptoms. While some symptoms are merely bothersome (crying), others can be life threatening (cough, gagging, choking). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0311-3DOI Listing
December 2018

An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Paediatr Drugs 2018 Dec;20(6):539-553

Department of Lung Transplant Service, The Alfred Hospital and Monash University, 55 Commercial Road, Melbourne, VIC, 3004, Australia.

Lung transplantation can offer life-prolonging therapy to children with otherwise terminal end-stage lung disease. However, infectious complications, like those experienced by their adult counterparts, are a significant cause of morbidity and mortality. These include bacteria, viruses, and fungi that infect the patient pretransplant and those that may be acquired from the donor or by the recipient in the months to years posttransplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0313-1DOI Listing
December 2018
3 Reads

The Effect of Alginate in Gastroesophageal Reflux in Infants.

Paediatr Drugs 2018 Dec;20(6):575-583

Kidz Health Castle, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan, 101, 1090, Brussels, Belgium.

Background: Guidelines are contradictory regarding the use of alginate in infants with persisting gastroesophageal reflux (GER). While The British National Institute for Health and Care (NICE) guidelines consider alginate as a treatment option, the guidelines of the European and North-American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN, NASPGHAN) do not recommend alginates.

Aims: We assessed the efficacy of alginate to reduce GER episodes in infants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0314-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267531PMC
December 2018
6 Reads

Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding.

Paediatr Drugs 2018 Dec;20(6):511-521

Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8884, USA.

Pediatric patients often have poor pregnancy outcomes. Systemic lupus erythematosus predominantly impacts women in their second to fourth decade of life, with childhood-onset disease being particularly aggressive. Reproductive issues are an important clinical consideration for pediatric patients with systemic lupus erythematosus (SLE), as maintaining good disease control and planning a pregnancy are important for maternal and fetal outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0312-2DOI Listing
December 2018
1 Read

Diversified Pediatric Pharmacoepidemiology: An International Priority.

Authors:
Stuart M MacLeod

Paediatr Drugs 2018 10;20(5):383-384

Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0308-yDOI Listing
October 2018

Prevention and Management of Bleeding Episodes in Children with Hemophilia.

Authors:
Rolf C R Ljung

Paediatr Drugs 2018 Oct;20(5):455-464

Department of Clinical Sciences-Paediatrics, Lund University, Lund, Sweden.

Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrations are still necessary. The half-lives of these products have now been extended (EHL) by fusion with albumin, the Fc-portion of IgG, or by being PEGylated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0307-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153959PMC
October 2018
7 Reads

Sexually Transmitted Infections in Pregnant Women: Integrating Screening and Treatment into Prenatal Care.

Paediatr Drugs 2018 Dec;20(6):501-509

Pediatric Infectious Diseases, University of Florida College of Medicine Jacksonville, 841 Prudential Drive, Suite # 1130, Jacksonville, FL, 32207, USA.

Chlamydia, gonorrhea, and syphilis continue to be significant burdens to the health of pregnant women and their children despite easy and effective guidance for screening and treatment. Specific guidelines exist for screening for these infections as well as treatment and follow-up. In this article, we review the epidemiology of chlamydia, gonorrhea, and syphilis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0310-4DOI Listing
December 2018

A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.

Paediatr Drugs 2018 Oct;20(5):483-495

Duke Clinical Research Institute, Durham, NC, USA.

Background And Aims: Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers. Subsequently, we developed a population-based pharmacokinetic (PopPK) model to characterize pantoprazole disposition and evaluated appropriate pantoprazole dosing strategies for obese pediatric patients, using simulation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0305-1
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0305-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178956PMC
October 2018
1 Read

The Challenges of Cortisol Replacement Therapy in Childhood: Observations from a Case Series of Children Treated with Modified-Release Hydrocortisone.

Paediatr Drugs 2018 Dec;20(6):567-573

Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK.

Background: Hydrocortisone is the preferred treatment for adrenal insufficiency in childhood. A small minority of children experience low cortisol concentrations and symptoms of cortisol insufficiency, poorly responsive to modifications in dosing. We speculated that treatment with modified-release hydrocortisone Plenadren may be beneficial in these selected patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0306-0
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0306-0DOI Listing
December 2018
8 Reads

Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants.

Paediatr Drugs 2018 Oct;20(5):475-481

Department of Neonatology, Celal Bayar University Faculty of Medicine, Manisa, Turkey.

Background: Given the severity and high mortality of multidrug-resistant Gram-negative bacilli (MDR-GNB) infections, the use of colistin will increase in patients with MDR-GNB infection.

Objective: This study aims to assess the efficacy and safety of intravenous colistin in very low birth weight (VLBW; birth weight < 1500 g) preterm infants.

Methods: We retrospectively analyzed the medical records of patients who received colistin between June 2016 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0301-5DOI Listing
October 2018
6 Reads

Methadone for Pain Management in Children with Cancer.

Paediatr Drugs 2018 Oct;20(5):409-416

Division of Anesthesia, Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA.

Methadone is a synthetic opioid with unique pharmacodynamic and pharmacokinetic properties. It is effective in treating both nociceptive and neuropathic pain, which commonly co-exist in children with cancer. Upon reviewing the literature describing the use of methadone in pediatric oncology patients, publications are limited in number and low in quality of evidence; nevertheless, there is support for the safety and efficacy of methadone in treating pain in children with cancer, particularly when pain is refractory to conventional treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0304-2DOI Listing
October 2018
1 Read

Trends in Outpatient Prescription Medicine Use in New Zealand Children 2010-2015: A National Population-Based Study.

Paediatr Drugs 2018 Oct;20(5):465-474

Best Practice Advocacy Centre, Dunedin, 9016, New Zealand.

Background: Research examining trends in the outpatient prescription medicine use of New Zealand children is limited.

Objectives: Our objective was to provide an overview of prescription medicine use in New Zealand children and assess changing patterns in use from 2010 to 2015.

Methods: We conducted a retrospective cohort study including all New Zealand primary care-registered children aged < 18 years using data from the national pharmaceutical claims database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0303-3DOI Listing
October 2018

Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents.

Paediatr Drugs 2018 Jul 12. Epub 2018 Jul 12.

Department of Pediatrics, University of L'Aquila, Via Vetoio, 1. Coppito, L'Aquila, Italy.

Selecting the most appropriate antiepileptic drug (AED) or combination of drugs for each patient and identifying the most suitable therapeutic regimen for their needs is increasingly challenging, especially among pediatric populations. In fact, the pharmacokinetics of several drugs vary widely in children with epilepsy because of age-related factors, which can influence the absorption, distribution, metabolism, and elimination of the pharmacological agent. In addition, individual factors, such as seizure type, associated comorbidities, individual pharmacokinetics, and potential drug interactions, may contribute to large fluctuations in serum drug concentrations and, therefore, clinical response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0302-4DOI Listing
July 2018
11 Reads

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Paediatr Drugs 2018 Oct;20(5):395-408

Division of Pediatric Hematology/Oncology/Bone and Marrow Transplant, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA.

Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients. Many therapies are currently being investigated, from immunomodulatory agents to adoptive cell therapy, bispecific T-cell engagers, oncolytic virotherapy, and checkpoint inhibition. One of the most exciting immunotherapies recently FDA approved is the use of CD19 chimeric antigen receptor T cells for pre-B-cell acute lymphoblastic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0297-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153971PMC
October 2018
2 Reads

Current Challenges in Neonatal Resuscitation: What is the Role of Adrenaline?

Paediatr Drugs 2018 Jun 19. Epub 2018 Jun 19.

Department of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy.

Adrenaline, also known as epinephrine, is a hormone, neurotransmitter, and medication. It is the best established drug in neonatal resuscitation, but only weak evidence supports current recommendations for its use. Furthermore, the available evidence is partly based on extrapolations from adult studies, and this introduces further uncertainty, especially when considering the unique physiological characteristics of newly born infants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0300-6DOI Listing
June 2018
2 Reads

Pharmacotherapy for Persistent Posttraumatic Headaches in Children and Adolescents: A Brief Review of the Literature.

Authors:
Joanne Kacperski

Paediatr Drugs 2018 Jun 7. Epub 2018 Jun 7.

Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 2015, Cincinnati, OH, 45229-3039, USA.

Concussion, now most often referred to as mild traumatic brain injury in recent literature, is common in pediatrics, and headache is often the most common complaint post-injury. Although most children and adolescents recover within 1-2 weeks, some develop frequent and debilitating headaches that can last for months or longer. Most clinicians would agree on the importance of managing both acute and persistent posttraumatic headaches appropriately to speed recovery, minimize disability, maximize function, and improve quality of life, but there are no well-established guidelines to instruct physicians in doing so. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0299-8DOI Listing

The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia.

Paediatr Drugs 2018 Aug;20(4):293-301

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Prophylactic eradication of central nervous system (CNS) leukaemia is the current standard of care in treating childhood acute lymphoblastic leukaemia (ALL). This is conventionally achieved through regular lumbar punctures with intrathecal injections of methotrexate into the cerebrospinal fluid (CSF). Ommaya reservoirs are subcutaneous implantable devices that provide a secure route of drug delivery into the CSF via an intraventricular catheter. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0298-9
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0298-9DOI Listing
August 2018
16 Reads

Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies.

Paediatr Drugs 2018 Aug;20(4):337-351

Department of Pediatric Gastroenterology, Université Libre de Bruxelles, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.

Helicobacter pylori infection is acquired mainly in childhood and remains an essential cause of peptic ulcer disease and gastric cancer. This article provides commentary on the last ESPGHAN/NASPGHAN guidelines and on publications made after the consensus conference of 2015. The majority of infected children are asymptomatic and pediatric studies do not support a role for H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0296-yDOI Listing
August 2018
3 Reads

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.

Paediatr Drugs 2018 Aug;20(4):365-374

Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.

Background: In view of the increased use of metformin in obese adolescents, the aim of this study was to determine the pharmacokinetics of metformin in overweight and obese adolescents.

Methods: In overweight and obese adolescents receiving metformin 500 or 1000 mg twice daily for 37 weeks during a clinical trial, blood samples were collected over 8 h during an oral glucose tolerance test. Population pharmacokinetic modeling was performed using NONMEM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0293-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028885PMC
August 2018
3 Reads

Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.

Paediatr Drugs 2018 May 9. Epub 2018 May 9.

Texas Liver Institute, 607 Camden Street, San Antonio, TX, 78215, USA.

The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased substantially in the past two decades and NAFLD has now become the most common cause of chronic liver disease in children and adolescents. NAFLD is a broad clinicopathologic spectrum ranging from simple steatosis to varying degrees of necroinflammation called nonalcoholic steatohepatitis (NASH), leading to fibrosis and subsequently to cirrhosis. Despite the increasing prevalence and progressive nature of NAFLD even among children, therapy for NAFLD in both adults and children are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0292-2DOI Listing
May 2018
3 Reads

Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.

Paediatr Drugs 2018 May 8. Epub 2018 May 8.

Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France.

Background: The application of population pharmacokinetic models and Bayesian methods offers the potential to develop individualized therapeutic approaches.

Objectives: The current study presents an external evaluation of a vancomycin pharmacokinetic model in a pediatric cancer population and proposes an easy-to-use chart for clinicians for a priori vancomycin schedule adaptation to achieve target concentration.

Methods: External evaluation of a population pharmacokinetic model of vancomycin administered via continuous infusion was realized in a new retrospective dataset of pediatric patients with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0295-zDOI Listing
May 2018
2 Reads

Dose-Dependent Teratology in Humans: Clinical Implications for Prevention.

Paediatr Drugs 2018 Aug;20(4):331-335

Faculty of Medicine, Hebrew University Hadassah Medical School, Jerusalem, Israel.

Since the inception of clinical teratology, the vast majority of scientific work has focused on identification of drugs and environmental agents causing malformations in humans as a dichotomous variable (i.e. yes or no), as well as the relative and absolute risks of such occurrences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0294-0DOI Listing
August 2018
3 Reads

Using Lithium in Children and Adolescents with Bipolar Disorder: Efficacy, Tolerability, and Practical Considerations.

Paediatr Drugs 2018 Aug;20(4):303-314

Department of Psychiatry, Kennedy Krieger Institute, Johns Hopkins University School of Medicine, 716 N. Broadway, Baltimore, MD, 21205, USA.

Lithium has been an intriguing treatment option in psychiatry for over a century. While seemingly just a simple elemental compound, it has powerful treatment effects for both depression and bipolar disorder. The evidence base for treatment of pediatric bipolar disorder is relatively small, but, in recent years, additional clinical trial data have enabled lithium to re-emerge as a valuable and, in many cases, preferred treatment. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0289-x
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0289-xDOI Listing
August 2018
4 Reads

Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.

Paediatr Drugs 2018 06;20(3):291

AbbVie GK, Mita 3-5-27, Minato-ku, Tokyo, 108-6302, Japan.

"Newborns, infants, or young children aged 24 months and under who have Down syndrome, and children ≤ 24 months of age without a current hs-CHD if they had experienced persistent respiratory symptoms or regular outpatient treatment due to a respiratory tract infection in previous RSV seasons were also eligible for the study." Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0291-3
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0291-3DOI Listing
June 2018
10 Reads

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.

Paediatr Drugs 2018 Aug;20(4):353-363

Johns Hopkins University and Kennedy Krieger Institute, Baltimore, Maryland, USA.

Background: Major depressive disorder (MDD) is a serious illness in children and adolescents. Vilazodone is a selective serotonin reuptake inhibitor approved for MDD in adults. This study evaluated the efficacy, safety, and tolerability of vilazodone in adolescent patients, ages 12-17 years, with MDD (NCT01878292). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0290-4
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0290-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028869PMC
August 2018
5 Reads

A Review of the New Antiepileptic Drugs for Focal-Onset Seizures in Pediatrics: Role of Extrapolation.

Paediatr Drugs 2018 Jun;20(3):249-264

Department of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, VT, USA.

Most antiepileptic drugs (AEDs) receive regulatory approval for children years after the drug is available in adults, encouraging off-label use of the drug in children and hindering attempts to obtain quality pediatric data in controlled trials. Extrapolating adult efficacy data to pediatrics can reduce the time between approval in adults and that in children. To extrapolate efficacy from adults to children, several assumptions must be supported, such as (1) a similar disease progression and response to interventions in adults and children, and (2) similar exposure response in adults and children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0286-0DOI Listing
June 2018
3 Reads

Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling.

Paediatr Drugs 2018 Jun;20(3):265-272

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P. O. Box 2457, Riyadh, 11451, Saudi Arabia.

Objective: Our objective was to determine the population pharmacokinetic parameters of amikacin in pediatric patients to contribute to the future development of a revised optimum dose and population-specific dosing regimens.

Methods: We performed a retrospective chart review in non-critical pediatric patients (aged 1-12 years) who received amikacin for suspected or proven Gram-negative infection at a university hospital. The population pharmacokinetic models were developed using Monolix 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0288-yDOI Listing
June 2018
8 Reads

Correction to: Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis.

Paediatr Drugs 2018 04;20(2):207

Department of Pediatrics, The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA.

In the print publication the name of the seventh author was incorrectly published. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0285-1DOI Listing
April 2018
3 Reads

The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence.

Paediatr Drugs 2018 Jun;20(3):235-247

Pediatric Clinic, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Piazza Menghini 1, 06129, Perugia, Italy.

Recurrent abdominal pain (RAP) is one of the most common health complaints in both children and adults. Although RAP is considered a functional disorder rather than an organic disease, affected children and their families can still experience anxiety and concerns that can interfere with school, sports, and regular daily activities and lead to frequent attendances at pediatric emergency departments or pediatric gastroenterology clinics. Our review shows experts do not agree on a universally proven management that will work on every child presenting with functional abdominal pain (FAP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0287-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954057PMC
June 2018
6 Reads

Ethical Considerations for the Participation of Children of Minor Parents in Clinical Trials.

Paediatr Drugs 2018 Jun;20(3):215-222

Medical Psychology (in Pediatrics and Psychiatry), Columbia University Medical Center-College of Physicians and Surgeons, New York, NY, USA.

Children of minor parents are under-represented in clinical trials. This is largely because of the ethical, legal, and regulatory complexities in the enrolment, consent, and appropriate access of children of minor parents to clinical research. Using a case-based approach, we examine appropriate access of children of minor parents in an international vaccine trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0280-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954045PMC
June 2018
8 Reads

Effect of Levocarnitine on the Therapeutic Efficacy of Conventional Therapy in Children with Dilated Cardiomyopathy: Results of a Randomized Trial in 29 Children.

Paediatr Drugs 2018 Jun;20(3):285-290

Department of Pediatric Cardiovasology, Children's Medical Center, The Second Xiangya Hospital, Central South University, No. 139 Ren-min Middle Road, Changsha, 410011, Hunan, People's Republic of China.

Background: The effect of levocarnitine supplementation has not been evaluated in children with dilated cardiomyopathy (DCM).

Objective: The aim of this study was to explore the effect of oral levocarnitine supplementation in pediatric patients with DCM.

Methods: Twenty-nine children with DCM (17 male, 12 female, aged 1 month to 13 years) were divided into two groups according to a simple randomization: control group (n = 10) and experimental group (n = 19). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-018-0284-2
Publisher Site
http://dx.doi.org/10.1007/s40272-018-0284-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954011PMC
June 2018
13 Reads
1.720 Impact Factor

Rotavirus Vaccines: Effectiveness, Safety, and Future Directions.

Paediatr Drugs 2018 Jun;20(3):223-233

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Rotavirus is the leading cause of diarrheal death among children < 5 years old worldwide, estimated to have caused ~ 215,000 deaths in 2013. Prior to rotavirus vaccine implementation, > 65% of children had at least one rotavirus diarrhea illness by 5 years of age and rotavirus accounted for > 40% of all-cause diarrhea hospitalizations globally. Two live, oral rotavirus vaccines have been implemented nationally in > 100 countries since 2006 and their use has substantially reduced the burden of severe diarrheal illness in all settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0283-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955791PMC
June 2018
4 Reads

The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.

Paediatr Drugs 2018 Apr;20(2):153-164

Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.

Background: In adults, the area under the concentration-time curve (AUC) divided by the minimum inhibitory concentration (MIC) is associated with better clinical and bacteriological response to vancomycin in patients with methicillin-resistant Staphylococcus aureus who achieve target AUC/MIC ≥ 400. This target is often extrapolated to pediatric patients despite the lack of similar evidence. The impracticalities of calculating the AUC in practice means vancomycin trough concentrations are used to predict the AUC/MIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0282-4DOI Listing
April 2018
9 Reads

Optimizing the Dosing of Intravenous Theophylline in Acute Severe Asthma in Children.

Paediatr Drugs 2018 Jun;20(3):209-214

Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Eaton Road, Liverpool, L12 2AP, UK.

Optimizing the management of children presenting with acute severe asthma is of utmost importance to minimize hospital stays, morbidity, and mortality. Intravenous medications, including theophyllines, are used as second-line treatments for children experiencing a life-threatening exacerbation. For intravenous theophylline (aminophylline), guidelines and formularies recommend a target therapeutic range between 10 and 20 mg/l, with the commonest regimen being a loading dose of 5 mg/kg followed by an infusion calculated by age and weight. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0281-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954054PMC
June 2018
7 Reads

Correction to: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.

Paediatr Drugs 2018 04;20(2):205

Drug Metabolism and Pharmacokinetics, Shire, 300 Shire Way, Lexington, MA, 02421, USA.

The article "Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a PhysiologicallyBased Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers", written by Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 02nd November, 2017 without open access. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0275-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856870PMC
April 2018
13 Reads

Differences in Pediatric Headache Prescription Patterns by Diagnosis.

Paediatr Drugs 2018 Jun;20(3):273-284

Pediatric Headache Program, Division of Pain Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, 9 Hope Ave, Waltham, MA, 02453, USA.

Background: Few studies have reported prescription patterns for headache medication.

Objective: The aim was to present the rates of specific medication prescribed to pediatric patients diagnosed with migraine, tension-type headache (TTH), and new daily persistent headache (NDPH), as well as differences in those prescription patterns by diagnosis, age, and gender.

Patients And Methods: A query using the i2b2 platform yielded 14,591 patients [migraine 10,547 (72. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0279-4DOI Listing
June 2018
7 Reads

Method Development for Clinical Comprehensive Evaluation of Pediatric Drugs Based on Multi-Criteria Decision Analysis: Application to Inhaled Corticosteroids for Children with Asthma.

Paediatr Drugs 2018 Apr;20(2):195-204

Clinical Research Center, Beijing Children's Hospital, Capital Medical University, No. 56 Nanlishi Road, Beijing, 100045, China.

Background: Establishing a comprehensive clinical evaluation system is critical in enacting national drug policy and promoting rational drug use. In China, the 'Clinical Comprehensive Evaluation System for Pediatric Drugs' (CCES-P) project, which aims to compare drugs based on clinical efficacy and cost effectiveness to help decision makers, was recently proposed; therefore, a systematic and objective method is required to guide the process.

Methods: An evidence-based multi-criteria decision analysis model that involved an analytic hierarchy process (AHP) was developed, consisting of nine steps: (1) select the drugs to be reviewed; (2) establish the evaluation criterion system; (3) determine the criterion weight based on the AHP; (4) construct the evidence body for each drug under evaluation; (5) select comparative measures and calculate the original utility score; (6) place a common utility scale and calculate the standardized utility score; (7) calculate the comprehensive utility score; (8) rank the drugs; and (9) perform a sensitivity analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0278-5DOI Listing
April 2018
21 Reads

Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.

Paediatr Drugs 2018 Apr;20(2):173-180

Division of Pediatric Gastroenterology, Nationwide Children's Hospital, Ohio State University, Columbus, OH, USA.

Background: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-017-0277-6
Publisher Site
http://dx.doi.org/10.1007/s40272-017-0277-6DOI Listing
April 2018
18 Reads

Pediatric Asthma Management in China: Current and Future Challenges.

Paediatr Drugs 2018 Apr;20(2):105-110

Department of Pediatrics, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 200080, People's Republic of China.

The purpose of this report was to review the state of asthma diagnosis and treatment in China and to examine challenges in achieving earlier diagnosis and treatment. The prevalence of asthma in children in China has increased over past decades, and data published in 2013 indicated a prevalence of 3.0% in children aged 0-14 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0276-7DOI Listing
April 2018
8 Reads

Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.

Authors:
Henriette Farkas

Paediatr Drugs 2018 Apr;20(2):135-151

3rd Department of Internal Medicine, Hungarian Angioedema Center, Semmelweis University, Kútvölgyi street 4, Budapest, 1125, Hungary.

Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is a form of bradykinin-mediated angioedema. It is a rare disorder with an onset during childhood in most instances. Therefore, familiarity with the options for the management of pediatric cases is indispensable. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40272-017-0273-x
Publisher Site
http://dx.doi.org/10.1007/s40272-017-0273-xDOI Listing
April 2018
18 Reads

Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.

Paediatr Drugs 2018 Apr;20(2):165-171

Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste, Italy.

Objectives: Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated, yet they can be associated with serious adverse events (SAEs) in a minority of patients. We examined the incidence of SAEs in a pediatric referral center for chronic rheumatologic and gastroenterological inflammatory disorders.

Methods: Retrospective analysis of SAEs occurring during treatment with anti-TNF-α agents in patients with juvenile idiopathic arthritis (JIA) (n = 78)  or pediatric-onset inflammatory bowel disease (IBD) (n = 105) seen at the Institute for Maternal and Child Health IRCCS "Burlo Garofolo" in Trieste, Italy, between June 2001 and February 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0267-8DOI Listing
April 2018
11 Reads
1.720 Impact Factor

Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.

Paediatr Drugs 2018 Apr;20(2):121-134

The Johns Hopkins University and the Kennedy Krieger Institute, Baltimore, MD, USA.

Asenapine, administered as a twice-daily (BID) sublingual tablet, is approved in the US as monotherapy for the acute treatment of manic and mixed episodes of bipolar I disorder in children and adolescents aged 10-17 years based on the positive results of one 3-week, double-blind, placebo-controlled study; the recommended dose is 2.5-10 mg BID. Although asenapine has been studied in pediatric patients with schizophrenia, it is not approved for this indication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0274-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856894PMC
April 2018
5 Reads

Agents in Development for Childhood Acute Lymphoblastic Leukemia.

Paediatr Drugs 2018 Apr;20(2):111-120

Center for Cancer and Blood Disorders, Children's Hospital Colorado, Pediatric Hematology/Oncology/Bone Marrow Transplant, University of Colorado School of Medicine, 13123 East 16th Av, Box B115, Aurora, CO, 80045, USA.

Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Standard chemotherapy has afforded outstanding outcomes for many patients; however, there remain some sub-groups with high-risk features, refractory disease, and patients that  relapse who have a poor prognosis with conventional treatments. Over the past decade, there have been significant advances in newer treatment options, including improved monoclonal antibody therapies, T cell engagers, and chimeric antigen T-cell receptor products, all of which have changed the landscape for patients who relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-017-0268-7DOI Listing
April 2018
7 Reads